{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,20]],"date-time":"2026-02-20T23:12:08Z","timestamp":1771629128791,"version":"3.50.1"},"reference-count":45,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,2,1]],"date-time":"2023-02-01T00:00:00Z","timestamp":1675209600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100009045","name":"Uniwersytet Jagiello\u0144ski Collegium Medicum","doi-asserted-by":"publisher","award":["K\/ZDS\/002936"],"award-info":[{"award-number":["K\/ZDS\/002936"]}],"id":[{"id":"10.13039\/100009045","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","internationaljournalofcardiology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Cardiology"],"published-print":{"date-parts":[[2023,2]]},"DOI":"10.1016\/j.ijcard.2022.11.026","type":"journal-article","created":{"date-parts":[[2022,11,21]],"date-time":"2022-11-21T15:55:44Z","timestamp":1669046144000},"page":"110-117","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Therapy with high-dose statins reduces soluble P-selectin: The impact on plasma fibrin clot properties"],"prefix":"10.1016","volume":"373","author":[{"given":"Jakub","family":"Siudut","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joanna","family":"Pud\u0142o","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ma\u0142gorzata","family":"Konieczy\u0144ska","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maciej","family":"Polak","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jacek","family":"Jawie\u0144","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anetta","family":"Undas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijcard.2022.11.026_bb0005","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1111\/j.1365-2141.2004.05032.x","article-title":"P-selectin in haemostasis","volume":"126","author":"Andr\u00e9","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0010","doi-asserted-by":"crossref","first-page":"848","DOI":"10.1038\/359848a0","article-title":"Leukocyte accumulation promoting fibrin deposition is mediated in vivo by P-selectin on adherent platelets","volume":"359","author":"Palabrica","year":"1992","journal-title":"Nature."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0015","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1172\/JCI2592","article-title":"Modulation of monocyte-endothelial cell interactions by platelet microparticles","volume":"102","author":"Barry","year":"1998","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0020","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1084\/jem.190.6.803","article-title":"The glycoprotein Ib-IX-V complex is a platelet counterreceptor for P-selectin","volume":"190","author":"Romo","year":"1999","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0025","doi-asserted-by":"crossref","first-page":"8767","DOI":"10.1073\/pnas.91.19.8767","article-title":"P-selectin induces the expression of tissue factor on monocytes","volume":"91","author":"Celi","year":"1994","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0030","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1016\/S0002-9149(00)01502-2","article-title":"Relation of soluble and platelet p-selectin to early outcome in patients with acute myocardial infarction after thrombolytic therapy","volume":"87","author":"Gurbel","year":"2001","journal-title":"Am. J. Cardiol."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0035","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/00001721-199704000-00008","article-title":"Soluble P-selectin in hyperlipidaemia with and without symptomatic vascular disease: relationship with von Willebrand factor","volume":"8","author":"Blann","year":"1997","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.ijcard.2022.11.026_bb0040","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1177\/1358836X9900400104","article-title":"Decrease in P-selectin levels in patients with hypercholesterolaemia and peripheral arterial occlusive disease after lipid-lowering treatment","volume":"4","author":"Kirk","year":"1999","journal-title":"Vasc. Med."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0045","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1161\/ATVBAHA.108.183160","article-title":"Antiplatelet actions of statins and fibrates are mediated by PPARs","volume":"29","author":"Ali","year":"2009","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0050","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1161\/CIRCULATIONAHA.112.095554","article-title":"Immediate antioxidant and antiplatelet effect of atorvastatin via inhibition of Nox2","volume":"126","author":"Pignatelli","year":"2012","journal-title":"Circulation."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0055","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/6661847","article-title":"Effect of statins on platelet activation and function: from molecular pathways to clinical effects","volume":"2021","author":"Nenna","year":"2021","journal-title":"Biomed. Res. Int."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0060","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1159\/000145327","article-title":"Statin potentiates human platelet eNOS activity without enhancing eNOS mRNA and protein levels","volume":"26","author":"Yemisci","year":"2008","journal-title":"Cerebrovasc. Dis."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0065","doi-asserted-by":"crossref","first-page":"1300","DOI":"10.1089\/ars.2013.5527","article-title":"Statins as regulators of redox signaling in platelets","volume":"20","author":"Violi","year":"2014","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0070","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1161\/CIRCULATIONAHA.112.145334","article-title":"Statins as antithrombotic drugs","volume":"127","author":"Violi","year":"2013","journal-title":"Circulation."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0075","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.atherosclerosis.2010.01.044","article-title":"Evaluation of the lipid lowering ability, anti-inflammatory effects and clinical safety of intensive therapy with Zhibitai, a Chinese traditional medicine","volume":"211","author":"Xu","year":"2010","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0080","doi-asserted-by":"crossref","first-page":"1707","DOI":"10.3390\/biomedicines9111707","article-title":"Systematic review and meta-analysis of the effect of statins on circulating E-selectin, L-selectin, and P-selectin","volume":"9","author":"Zinellu","year":"2021","journal-title":"Biomedicines."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0085","doi-asserted-by":"crossref","DOI":"10.1016\/j.vph.2022.106977","article-title":"Intensive low-density lipoprotein cholesterol lowering improves fibrin clot properties: association with lipoproteins and C-reactive protein","volume":"144","author":"Siudut","year":"2022","journal-title":"Vasc. Pharmacol."},{"issue":"2016","key":"10.1016\/j.ijcard.2022.11.026_bb0090","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.1093\/eurheartj\/ehw272","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias","volume":"37","author":"Catapano","year":"2016","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0095","doi-asserted-by":"crossref","first-page":"850","DOI":"10.33963\/KP.15529","article-title":"Statins plus ezetimibe in the era of proprotein convertase subtilisin\/ kexin type 9 inhibitors","volume":"78","author":"de Luca","year":"2020","journal-title":"Kardiol. Pol."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0100","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.33963\/KP.a2021.0088","article-title":"Thromboembolism and bleeding in patients with atrial fibrillation and stage 4 chronic kidney disease: impact of biomarkers","volume":"79","author":"Matusik","year":"2021","journal-title":"Kardiol. Pol."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0105","doi-asserted-by":"crossref","first-page":"4272","DOI":"10.1182\/blood-2009-05-222380","article-title":"Altered fibrin clot structure\/function in patients with idiopathic venous thromboembolism and in their relatives","volume":"114","author":"Undas","year":"2009","journal-title":"Blood."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0110","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/S0021-9150(01)00696-7","article-title":"Reduced expression of endothelial cell markers after 1 year treatment with simvastatin and atorvastatin in patients with coronary heart disease","volume":"162","author":"Seljeflot","year":"2002","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0115","article-title":"Fibrin clot properties in coronary artery disease: new determinants and prognostic markers","volume":"131","author":"Larsen","year":"2021","journal-title":"Pol. Arch. Intern. Med."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0120","doi-asserted-by":"crossref","first-page":"3808","DOI":"10.2174\/138161210794455120","article-title":"The antiplatelet and antithrombotic actions of statins","volume":"16","author":"Mitsios","year":"2010","journal-title":"Curr. Pharm. Des."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0125","doi-asserted-by":"crossref","first-page":"2567","DOI":"10.1161\/01.ATV.0000241589.52950.4c","article-title":"Altered fibrin architecture is associated with hypofibrinolysis and premature coronary atherothrombosis","volume":"26","author":"Collet","year":"2006","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0130","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.3390\/jcm10132999","article-title":"Fibrin clot properties in atherosclerotic vascular disease: from pathophysiology to clinical outcomes","volume":"10","author":"Z\u0105bczyk","year":"2021","journal-title":"J. Clin. Med."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0135","doi-asserted-by":"crossref","DOI":"10.1016\/j.jprot.2020.103946","article-title":"Plasma fibrin clot proteomics in patients with acute pulmonary embolism\u00a0: association with clot properties","volume":"229","author":"Bryk","year":"2020","journal-title":"J. Proteome"},{"key":"10.1016\/j.ijcard.2022.11.026_bb0140","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1186\/s12014-017-9173-x","article-title":"Optimization of quantitative proteomic analysis of clots generated from plasma of patients with venous thromboembolism","volume":"14","author":"Stachowicz","year":"2017","journal-title":"Clin. Proteomics"},{"key":"10.1016\/j.ijcard.2022.11.026_bb0145","doi-asserted-by":"crossref","first-page":"1","DOI":"10.3109\/09537104.2015.1042967","article-title":"Altered plasma fibrin clot properties in essential thrombocythemia","volume":"7104","author":"Ma\u0142ecki","year":"2015","journal-title":"Platelets."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0150","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1016\/j.atherosclerosis.2014.10.020","article-title":"Coronary thrombus composition: links with inflammation, platelet and endothelial markers","volume":"237","author":"Sadowski","year":"2014","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0155","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1160\/TH10-12-0810","article-title":"Atorvastatin reduces thrombin generation and expression of tissue factor, P-selectin and GPIIIa on platelet-derived microparticles in patients with peripheral arterial occlusive disease","volume":"106","author":"Mobarrez","year":"2011","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0160","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1253\/circj.CJ-10-0110","article-title":"Pleiotropic effects of statins - basic research and clinical perspectives","volume":"74","author":"Zhou","year":"2010","journal-title":"Circ. J."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0165","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.atherosclerosis.2007.12.018","article-title":"Simvastatin alters human endothelial cell adhesion molecule expression and inhibits leukocyte adhesion under flow","volume":"200","author":"Eccles","year":"2008","journal-title":"Atherosclerosis."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0170","doi-asserted-by":"crossref","DOI":"10.1096\/fasebj.21.6.A1152-d","article-title":"Potential mechanisms of the anti-inflammatory effects of simvastatin in an in vitro flow model of inflammation","volume":"21","author":"Graham","year":"2007","journal-title":"FASEB J."},{"issue":"2020","key":"10.1016\/j.ijcard.2022.11.026_bb0175","first-page":"111","article-title":"ESC\/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk","volume":"41","author":"Mach","year":"2019","journal-title":"Eur. Heart J."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0180","doi-asserted-by":"crossref","first-page":"824","DOI":"10.1177\/2047487318825350","article-title":"Lifestyle and impact on cardiovascular risk factor control in coronary patients across 27 countries: results from the European Society of Cardiology ESC-EORP EUROASPIRE V registry","volume":"26","author":"Kotseva","year":"2019","journal-title":"Eur. J. Prev. Cardiol."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0185","article-title":"Optimal medical therapy in patients with stable coronary artery disease in Poland: the ISCHEMIA trial experience","volume":"131","author":"Praco\u0144","year":"2021","journal-title":"Pol. Arch. Intern. Med."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0190","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1161\/01.CIR.103.4.491","article-title":"Soluble P-selectin and the risk of future cardiovascular events","volume":"103","author":"Ridker","year":"2001","journal-title":"Circulation."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0195","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1097\/00001721-199710000-00002","article-title":"Increased soluble P-selectin following myocardial infarction: a new marker for the progression of atherosclerosis","volume":"8","author":"Blann","year":"1997","journal-title":"Blood Coagul. Fibrinolysis"},{"key":"10.1016\/j.ijcard.2022.11.026_bb0200","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1007\/s11239-012-0821-8","article-title":"Type 2 diabetes as a modifier of fibrin clot properties in patients with coronary artery disease","volume":"35","author":"Bochenek","year":"2013","journal-title":"J. Thromb. Thrombolysis"},{"key":"10.1016\/j.ijcard.2022.11.026_bb0205","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1055\/s-0038-1676563","article-title":"Prognostic impact of soluble P-selectin on long-term adverse cardiovascular outcomes in patients undergoing percutaneous coronary intervention","volume":"119","author":"Tscharre","year":"2019","journal-title":"Thromb. Haemost."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0210","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1097\/FJC.0000000000000233","article-title":"First-in-man study with inclacumab, a human monoclonal antibody against P-selectin","volume":"65","author":"Schmitt","year":"2015","journal-title":"J. Cardiovasc. Pharmacol."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0215","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1016\/j.jacc.2013.03.003","article-title":"Effects of the P-selectin antagonist Inclacumab on myocardial damage after percutaneous coronary intervention for non\u2013ST-segment elevation myocardial infarction","volume":"61","author":"Tardif","year":"2013","journal-title":"J. Am. Coll. Cardiol."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0220","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.116.004255","article-title":"Effects of the P-selectin antagonist inclacumab on myocardial damage after percutaneous coronary intervention according to timing of infusion: insights from the SELECT-ACS trial","volume":"5","author":"St\u00e4hli","year":"2016","journal-title":"J. Am. Heart Assoc."},{"key":"10.1016\/j.ijcard.2022.11.026_bb0225","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1016\/j.jacc.2015.10.071","article-title":"Effects of P-selectin antagonist Inclacumab in patients undergoing coronary artery bypass graft surgery","volume":"67","author":"St\u00e4hli","year":"2016","journal-title":"J. Am. Coll. Cardiol."}],"container-title":["International Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527322017132?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0167527322017132?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,28]],"date-time":"2025-09-28T20:58:57Z","timestamp":1759093137000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0167527322017132"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2]]},"references-count":45,"alternative-id":["S0167527322017132"],"URL":"https:\/\/doi.org\/10.1016\/j.ijcard.2022.11.026","relation":{},"ISSN":["0167-5273"],"issn-type":[{"value":"0167-5273","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Therapy with high-dose statins reduces soluble P-selectin: The impact on plasma fibrin clot properties","name":"articletitle","label":"Article Title"},{"value":"International Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijcard.2022.11.026","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}